MongoDB Inc. diskutieren
MongoDB, Inc. (NASDAQ: MDB) had its price target raised by analysts at Barclays PLC from $470.00 to $478.00. They now have an "overweight" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $495.00 price target on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target raised by analysts at KeyCorp from $500.00 to $543.00. They now have an "overweight" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target raised by analysts at Truist Financial Co. from $440.00 to $500.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target raised by analysts at Guggenheim from $250.00 to $272.00. They now have a "sell" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target raised by analysts at Citigroup Inc. from $515.00 to $550.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) was upgraded by analysts at DA Davidson from a "neutral" rating to a "buy" rating. They now have a $430.00 price target on the stock, up previously from $405.00.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its "sell" rating re-affirmed by analysts at Redburn Atlantic. They now have a $295.00 price target on the stock, down previously from $410.00.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target raised by analysts at Tigress Financial from $495.00 to $500.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) is now covered by analysts at Loop Capital. They set a "buy" rating and a $415.00 price target on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $465.00 price target on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Bank of America Co. from $500.00 to $470.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Robert W. Baird from $450.00 to $305.00. They now have an "outperform" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Morgan Stanley from $455.00 to $320.00. They now have an "overweight" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Piper Sandler from $480.00 to $350.00. They now have an "overweight" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Needham & Company LLC from $465.00 to $290.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Truist Financial Co. from $475.00 to $300.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Stifel Nicolaus from $435.00 to $300.00. They now have a "buy" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $480.00 to $300.00. They now have an "outperform" rating on the stock.
Ratings data for MDB provided by MarketBeat
MongoDB, Inc. (NASDAQ: MDB) had its price target lowered by analysts at Wells Fargo & Company from $450.00 to $300.00. They now have an "overweight" rating on the stock.
Ratings data for MDB provided by MarketBeat
Neueste Beiträge
Canaccord_Genuity_Gr in Ultragenyx Pharmaceutical Inc. diskutieren